Tag Archive for: CEO appointment

Commit Biologics appoints serial biotech founder as new CEO to take complement-powered immune engagers into the clinic

/in

Dr. Thomas L. F. Montgomery Andresen joins from T-Cypher Bio Follows breakthrough non-human primate data demonstrating deep B-cell depletion without cytokine release Commit is poised to nominate its first two clinical development candidates later in 2026 COPENHAGEN, Denmark — March 11, 2026 — Commit Biologics (“Commit”), a biotechnology company pioneering complement system activation and backed […]

Read more

Hans Schambye Appointed as Chief Executive Officer of BOOST Pharma

/in

Advancing development of lead candidate BT-101, a potential disease-modifying treatment for Brittle Bone Disease Preparing for Phase III development following promising data showing reduced fractures in affected children Stockholm, Sweden, February 10, 2026 – BOOST Pharma (“BOOST” or the “Company), a clinical‑stage biopharmaceutical company developing novel, first‑in‑class off-the-shelf cell therapies for rare, debilitating pediatric skeletal […]

Read more

Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines

/in

– 25+ years of biotherapeutics leadership, including serving as founding CEO of two NASDAQ-listed companies and securing over $500 million in funding – Expertise in advanced therapeutics development, driving multiple cell and gene therapy product candidates from discovery through to clinical trials COVENTRY, England, Jan. 8, 2026 /PRNewswire/ — NanoSyrinx, a synthetic biology company developing Nanosyringes™ as a novel platform for targeted intracellular delivery of biologic therapeutics, […]

Read more

Gergely Sved appointed CEO of Ellab

/in

27 March 2025 Hillerød, Denmark – Ellab, the leading provider of validation, monitoring, and calibration services and solutions, announces that it has appointed Gergely Sved as its new Chief Executive Officer (CEO), following the departure of Ludvig Enlund. Mr Sved will formally join the company in June, with Chief Financial Officer Andreas Morthorst acting as […]

Read more

Experienced Industry Leader Dr. Joerg Moeller Appointed as Chief Executive Officer of Antag Therapeutics

/in

Former Head of Global R&D at Bayer AG and an exceptional leader with a wealth of experience across biopharma Pivotal time of transition as the company prepares to start clinical development of its first-in-class lead candidate, AT-7687 in obesity AT-7687 offers a new mechanism of action, to set a new standard in obesity management Copenhagen, […]

Read more